- Numinus Wellness Inc. (NUMI) has received approval from Health Canada for its experiential training study for whole psilocybe cubensis tea therapy
- The clinical trial will use EnfiniTea, a whole mushroom psilocybe tea product carrying 25 milligrams of psilocybin for trial dosing
- EnfiniTea is produced using Numinus’ own validated strain of psilocybe cubensis BP-Star
- The initial results from the study are expected to be published in the second half of 2023
- Numinus Wellness Inc. (NUMI) is down 1.85 per cent, trading at $0.26 per share as of 12:59 p.m. EST
Numinus Wellness (NUMI) has received approval from Health Canada for its experiential training study.
The study will test the safety and clinical efficacy of whole psilocybe cubensis tea for therapeutic use.
Numinus Wellness develops and delivers innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
The clinical trial will use EnfiniTea, a whole mushroom psilocybe tea product carrying 25 milligrams of psilocybin for trial dosing.
EnfiniTea is produced using Numinus’ own validated strain of psilocybe cubensis BP-Star and is shelf stable, consistently dosed and economical to produce. The product has also been submitted to Health Canada to be included on the psilocybin supplier list for the federal Special Access Program, through which healthcare providers can apply to provide psilocybin-assisted therapy to eligible patients.
Also, the clinical trial will initially be conducted at Numinus’ clinic in Vancouver and will begin selecting volunteers in the next several weeks. Study subjects will be selected from qualified practitioners to provide psilocybin-assisted therapy. The initial results from the study are expected to be published in the second half of 2023.
The trial will include one preparatory session, one dosing session, and one integration session, which will be followed by an observation period as well as participant interviews and questionnaires. Each study volunteer will participate as a study participant receiving the protocol and as an observer for another participant’s sessions.
Numinus Wellness Inc. (NUMI) is down 1.85 per cent, trading at $0.26 per share as of 12:59 p.m. EST.